Design and synthesis of novel quinoxaline-2,3-dione AMPA/Gly(N) receptor antagonists: Amino acid derivatives

Journal of Medicinal Chemistry

Volumn 42, Issue 12, 1999, Pages 2266-2271

  Nikam, Sham S ^a   Cordon, John J ^a   Ortwine, Daniel F ^a   Heimbach, Tycho H ^a   Blackburn, Anthony C ^a   Vartanian, Mark G ^a   Nelson, Carrie B ^a   Schwarz, Roy D ^a   Boxer, Peter A ^a   Rafferty, Michael F ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,8,9,10 HEXAHYDRO 9 METHYL 6 NITROPYRIDO[3,4 F]QUINOXALINE 2,3 DIONE; 2,3 QUINOXALINEDIONE DERIVATIVE; 6 (1 IMIDAZOLYL) 7 NITRO 2,3 QUINOXALINEDIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; [(6 ETHYL 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YLMETHYL)METHYLAMINO]ACETIC ACID ETHYL ESTER; [(6 ETHYL 7 NITRO 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YLMETHYL)METHYLAMINO]ACETIC ACID AMMONIUM SALT; [(7 BROMO 6 ETHYL 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YLMETHYL)METHYLAMINO]ACETIC ACID; [(7 BROMO 6 VINYL 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YLMETHYL)METHYLAMINO]ACETIC ACID; AMPA RECEPTOR ANTAGONIST; GLYCINE RECEPTOR ANTAGONIST; NS 257; PNQX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; RECEPTOR AFFINITY; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICONVULSANTS; BINDING, COMPETITIVE; CEREBRAL CORTEX; DRUG DESIGN; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; MALE; MICE; MODELS, MOLECULAR; QUINOXALINES; RATS; RECEPTORS, AMPA; RECEPTORS, GLYCINE; SOLUBILITY; SYNAPTOSOMES;

EID: 0033577986     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980455n     Document Type: Article

References (22)

1. Lees, G. J. Therapeutic potential of AMPA Receptor ligands in neurological disorders. CNS Drugs 1995, 5, 51.
2. Collingridge, G.; Lester, R. Excitatory amino acid receptors in the vertebrate nervous system. Pharmcol. Rev. 1989, 40, 145.
3. Muir, K. W.; Lees, K. R. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995, 26, 503.
4. Doble, A. Excitatory amino acid receptors and neurodegeneration. Therapie 1995, 50, 337.
5. Meldrum, B.; Garthwaite, J. Excitatory amino acid neurotoxicity and neurodegenrative disease. Trends Pharmacol. Sci. 1990, 11, 379.
6. Nakanishi, S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992, 258, 597.
7. Monoghan, D. T.; Bridges, R. D.; Cotman, C. W. The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system. Annu. Rev. Pharmacol. Toxicol. 1990, 29, 365-402.
8. Bigge, C. F.; Boxer, P. A.; Ortwine, D. F. AMPA/KA receptors. Curr. Pharm. Des. 1996, 2, 397-412.
9. Bigge, C. F.; Nikam, S. S. AMPA receptor agonists, antagonists and modulators: their potential for clinical utility. Exp. Opin. Ther. Patents 1997, 7, 1099-1114.
10. Sheardown, M. J.; Nielson, E. O.; Hanson, A. J.; Jacobsen, P.; Honore, T. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo[f]quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990, 247, 571-574.
11. Watjen, F.; Bigge, C. F.; Jensen, L. H.; Boxer, P. A.; Lescosky, L. J.; Nielsen, E. O.; Malone, T. C.; Campbell, G. W.; Coughenour, L. L.; Rock, D. M.; Drejer, J.; Marcoux, F. W. NS 257 (1,2,3,6,7,8-hexahydro-3-(hydroxyimino)-N,N,7-trimethyl-2-oxobenzo[2,1-b:3,4- c′]dipyrrole-5-sulfonamide is a potent, systemically active AMPA receptor antagonist. Bioorg. Med. Chem. Lett. 1994, 4, 371-376.
12. Ohmori, J.; Sakamoto, S.; Kubota, H.; Shimizu-Sasamata, M.; Okada, M.; Kawasaki, S.; Hidaka, K.; Togami, J.; Furuya, T.; Murase, K. J. Med. Chem. 1994, 37, 467-475.
13. Bigge, C. F.; Malone, T. C.; Boxer, P. A.; Nelson, C. B.; Ortwine, D. F.; Schelkun, R. M.; Retz, D. M.; Lescosky, L. J.; Borosky, S. A.; Vartanian, M. G.; Schwarz, R. D.; Campbell, G. W.; Robichaud, L. J.; Watjen, F. J. Med. Chem. 1995, 38, 3720-3740.
14. Schielke, G. P.; Kupina, N. C.; Boxer, P. A.; Cordon, J. J.; Bigge, C. F.; Marcoux, F. W. Delayed treatment with the novel AMPA receptor antagonist PD152247 (PNQX), reduces lesion size following focal ischemia and reperfusion in the rat. J. Cereb. Blood Flow Metab. 1995, 15 (Suppl. 1), S372.
15. Acklin, P.; Allgeier, H.; Auberson, Y. P.; Bischoff, S.; Ofner, S.; Sauer, D.; Schmutz, M. Bioorg. Med. Chem. Lett. 1998, 8, 493-498 and references cited therein.
16. Nielson, E. O.; Cha, J. J.; Honore, T.; Penny, J. B.; Young, A. B. Thiocyanate stabilizes AMPA receptor binding to the quisqualate receptor. Eur. J. Pharmacol. 1988, 157, 197-203.
17. Nielson, E. O.; Cha, J. J.; Honore, T.; Penny, J. B.; Young, A. B. Thiocyanate stabilizes AMPA receptor binding to the quisqualate receptor. Eur. J. Pharmacol. 1988, 157, 197-203.
18. Johansen, T. H.; Drejer, J.; Watjen, F.; Nielsen, E. O. A novel non-NMDA receptor antagonist shows selective displacement of low-affinity [3H]kainate binding. Eur. J. Pharmacol. 1993, 246, 195-204.
19. 3H]kainic acid to receptor sites in rat brain. Mol. Pharmacol. 1979, 15, 492-505.
20. Jones, S. M.; Snell, L. D.; Johnson, K. M. Characterization of the binding of radioligands to the NMDA, phencyclidine, and glycine receptors in buffy coat membranes. J. Pharmacol. Methods 1989, 21, 161-168.
21. Litchfield, J. T.; Wilcoxon, F. A simplified method of evaluation dose-effect experiments. J. Pharmacol. 1949, 96, 99-113.
22. Krall, R. L.; Penry, J. K.; White, B. G.; Kupferberg, H. J.; Swinyard, E. A. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978, 19, 409-428.